Rephonic
Artwork for The Uromigos

The Uromigos

The Uromigos
Prostate Cancer
Bladder Cancer
Kidney Cancer
Clinical Trials
Pembrolizumab
Immunotherapy
Renal Cell Carcinoma
Non-Muscle Invasive Bladder Cancer
Belzutifan
Muscle-Invasive Bladder Cancer
Renal Cancer
Urothelial Cancer
Overall Survival
Enzalutamide
Biomarkers
Abiraterone
Adjuvant Therapy
PARP Inhibitors
Tar-200
Chemotherapy

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

PublishesTwice weeklyEpisodes501Founded7 years ago
Number of ListenersCategories
MedicineHealth & Fitness

Listen to this Podcast

Artwork for The Uromigos

Latest Episodes

Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.

Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.

Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

GU Cast | Urology Podcast
GU Cast | Urology PodcastProfessor Declan Murphy & Dr Renu Eapen
Two Onc Docs
Two Onc DocsSam and Karine
Plenary Session
Plenary SessionVinay Prasad, MD MPH
Oncology Decoded
Oncology DecodedOncology Decoded

Recent Guests

Ari Hakimi
First author on preclinical cancer cell paper on hypoxia and TKIs in RCC
Memorial Sloan Kettering Cancer Center
Episode: Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Lyn Voung
Senior author on the same preclinical study
Memorial Sloan Kettering Cancer Center
Episode: Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Neha Vapiwala
Radiation oncologist
University of Pennsylvania
Episode: Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Travis Zack
Chief Medical Officer at Open Evidence
Open Evidence
Episode: Episode 514: Artificial Intelligence in Cancer Drug Development
Bishoy Faltas
Medical oncologist focused on bladder cancer; runs a research laboratory
Episode: Episode 513: Trials and Tribulations of Investigator-initiated Research
Louise Emmett
Medical oncologist; expert on ENZAP translational data
St Vincent's Hospital, Sydney
Episode: Episode 512: ENZA-P Nature Medicine translational data
Tanya Dorff
Head of the Genitourinary Cancer Program
City of Hope
Episode: Episode 510: ADCs in Prostate Cancer
Mary Ellen Taplin
Guest, presented the Proteus data in the Ask-O-Plenary session
Dana-Farber Cancer Institute
Episode: Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Neeraj Aggarwal
Presented TALAPRO-3 data and discussed trial design
Cancer Center / academic research (inferred)
Episode: Episode 507: ASCO 2026 - TALAPRO-3

Hosts

Tom Powles
Co-host of The Uromigos; Professor of Genitourinary Oncology; Director of Barts Cancer Centre; affiliated with Queen Mary University of London and Barts Cancer Centre
Brian Rini
Host of The Uromigos; Ingram Professor of Medicine (Hematology/Oncology); affiliated with Vanderbilt-Ingram Cancer Center

Reviews

4.8 out of 5 stars from 174 ratings
  • Excellent resource for patients anddocs

    The Uromigos keep patients and doctors informed with the very latest studies and research in urogenital cancer. I appreciate their hopeful, upbeat and revealing interviews with cutting edge researchers.

    Apple Podcasts
    5
    Tea Green
    United Statesa year ago
  • Informative podcast

    This podcast is a one-stop shop for all things GU oncology. The information is balanced, up to date and relevant for anyone in this field

    Apple Podcasts
    5
    F93111111
    United Kingdom2 years ago
  • Great for staying up on GU oncology

    Drs. Powles and Rini are some of the most eminent current leaders in GU oncology. In this podcast, they discuss recent key studies in the field and really break down the key questions clinicians and patients want to know — are they clinically significant, will they change practice, and what are the next steps? Also, there are a lot of cheesy jokes which this humble listener somehow enjoys.

    Apple Podcasts
    5
    Attentive listener 12345
    United States3 years ago
  • Topical and interesting

    Great discussion of topical issues within the urology space from a engaging, experienced and knowledgeable group of oncologists.

    Apple Podcasts
    5
    Antman1805
    Australia3 years ago
  • Fantastic podcast

    This is a fantastic podcast! Great insight with provocative discussions (while keeping it lighthearted at the same time).... Thank you guys. Keep them coming....

    Apple Podcasts
    5
    Jacky4911
    United States5 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Engaging hosts balance data critique with approachable humor, making dense topics accessible.
Guests are subject-matter experts who translate complex trials for clinicians and patients.
Shows high-quality, up-to-date GU oncology data explained clearly.
Great resource for trainees and practicing oncologists alike.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Q: Which patients would it be reasonable to offer the Proteus approach to, given the current data and uncertainties?
Patients who strongly prefer surgical management, have high-risk features suggesting micrometastatic disease risk, and are willing to accept the added toxicity of short-term ARPI and ADT may be considered, but there is no clear biomarker-defined subset yet; careful shared decision-making is essential.
Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Q: Neha, what do you think is the additional benefit of perioperative hormone therapy on top of radiation therapy, given the Proteus results?
While there was an apparent improvement in certain pathologic endpoints, it did not consistently translate into metastasis-free survival by conventional imaging, and the overall survival impact remains uncertain, so the decision to add ADT and ARPI should be individualized based on patient risk, biomarker status, and tolerance for increased toxicity.
Episode 514: Artificial Intelligence in Cancer Drug Development
Q: What is the practical downside or limitation of AI-enabled medical literature tools today?
Limitations include the need for comprehensive licensed content to access full text, potential gaps when internet access is restricted, and ensuring the models handle nuance and evolving guidelines with appropriate caution.
Episode 514: Artificial Intelligence in Cancer Drug Development
Q: Travis, do you need humans to curate and validate the references, or could AI eventually generate guidelines and practice recommendations autonomously?
Humans are still essential for oversight, especially for novel information and edge cases. Open Evidence uses AI to compute references and assess evidence, but clinicians provide the judgment and context, and we're building systems to surface gaps and support expert input.
Episode 512: ENZA-P Nature Medicine translational data
Q: Why was a two-week lead-in of ENZA chosen for all patients before introducing Lutetium?
Preclinical data suggested AR blockade elevates PSMA expression within a window, so a two-week lead-in allowed measurement of upregulation prior to Lutetium addition to assess whether upregulated PSMA could translate into deeper tumor targeting.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Uromigos

What is The Uromigos about and what kind of topics does it cover?

The show consistently provides expert-led analysis of GU cancers, with a strong focus on trial design, biomarker-driven strategies, and real-world applicability of high-stakes data. Conversations span prostate, bladder, kidney cancers and emerging modalities like targeted ADCs, radioligand therapy, and AI-enabled evidence. Hosts guide rigorous debates about trial endpoints, regulatory implications, and how new data could shift practice, while maintaining a personable, accessible tone that blends humor with clinical insight. Noteworthy is the blend of frontline clinicians, translational scientists, regulatory voices, and senior researchers, which gives listeners a practical sense of what data means for patient care and decision-making in rea... more

Where can I find podcast stats for The Uromigos?

Rephonic provides a wide range of podcast stats for The Uromigos. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Uromigos and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Uromigos get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for The Uromigos, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Uromigos?

Rephonic provides comprehensive predictive audience data for The Uromigos, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Uromigos have?

To see how many followers or subscribers The Uromigos has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Uromigos?

These podcasts share a similar audience with The Uromigos:

1. GU Cast | Urology Podcast
2. Two Onc Docs
3. Prostate Cancer Update
4. Plenary Session
5. Oncology Decoded

How many episodes of The Uromigos are there?

The Uromigos launched 7 years ago and published 501 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Uromigos?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Uromigos?

Rephonic pulls ratings and reviews for The Uromigos from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Uromigos?

Rephonic provides full transcripts for episodes of The Uromigos. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Uromigos?

Recent guests on The Uromigos include:

1. Ari Hakimi
2. Lyn Voung
3. Neha Vapiwala
4. Travis Zack
5. Bishoy Faltas
6. Louise Emmett
7. Tanya Dorff
8. Mary Ellen Taplin

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days